Related by context. All words. (Click for frequent words.) 74 pharmacological therapies 74 pharmacological treatments 71 pharmacologic treatments 70 psychotherapies 70 pharmacological approaches 69 nonpharmacologic 68 pharmacological intervention 68 psychotherapeutic interventions 67 behavioral interventions 67 non pharmacological interventions 66 antioxidant supplementation 66 dietary interventions 66 pharmacotherapies 65 cognitive behavioral therapies 65 testosterone supplementation 65 pharmacologic interventions 65 comorbid depression 64 nonpharmacological 64 interpersonal psychotherapy 64 pharmacologic intervention 64 pathophysiological mechanisms 64 hypochondriasis 64 comorbid disorders 64 biopsychosocial 64 antithrombotic therapy 63 nonpharmacological treatments 63 neurocognitive deficits 63 antiplatelet therapies 63 pharmacologic 63 pharmacologic approaches 63 Cognitive behavioral 63 antidepressant efficacy 63 pharmacological therapy 63 Genetic predisposition 62 therapeutic regimens 62 Atypical antipsychotics 62 unmeasured factors 62 therapeutic interventions 62 poststroke depression 62 neuropsychiatric symptoms 62 biochemical abnormalities 62 agomelatine 62 neuroimaging studies 62 statins cholesterol lowering 62 dopamine antagonists 62 compensatory mechanisms 62 psychoeducation 62 antiangiogenic agents 62 androgen deprivation 62 probiotic supplementation 62 Calorie restriction 62 neuroleptics 62 androgen ablation 61 neuropsychological impairments 61 somatoform disorders 61 topical NSAIDs 61 inhaled bronchodilators 61 prostate carcinogenesis 61 pharmacologic therapies 61 antidepressive 61 GnRH agonists 61 nutrient supplementation 61 pharmacotherapeutic 61 psychopharmacological 61 meta analytic 61 EBV infection 61 colorectal carcinogenesis 61 pharmacological 61 diagnosing ADHD 61 neuroleptic 61 AChE inhibitors 61 nomograms 61 atypical neuroleptics 61 psychosocial variables 61 androgen depletion 61 analgesic medications 61 SRBD 61 neuropsychiatric diseases 60 pathophysiological 60 prognostic indicators 60 postoperative AF 60 pyridostigmine 60 underlying molecular mechanisms 60 physiologic mechanisms 60 adrenal function 60 impaired cognition 60 therapies 60 somatic symptoms 60 psychosocial stressors 60 aromatase inhibitor therapy 60 dietary antioxidants 60 calcium supplementation 60 neurocognitive function 60 biologic plausibility 60 platelet activation 60 lipid lowering agents 60 parkinsonian symptoms 60 corticosteroid therapy 60 intensive lipid lowering 60 neuropsychological assessment 60 antiangiogenic therapy 60 fluoxetine Prozac 60 metabolic abnormalities 60 Singh Manoux 60 CAM modalities 60 TNF alpha antagonist 60 cognitive deficits 60 neuronal dysfunction 60 β blockers 60 Cognitive therapy 60 alexithymia 60 pathophysiologic mechanisms 60 magnesium supplementation 60 psychodynamic psychotherapy 60 neuropsychological deficits 60 nondrug treatments 60 antidepressant therapy 60 inotropes 60 Cognitive impairment 60 HPA axis 60 perioperative morbidity 60 selenium supplementation 60 hyperalgesia 60 underlying pathophysiology 60 dopaminergic therapy 60 Antidepressant medications 60 depressive illnesses 60 psychopharmacologic 60 maladaptive behaviors 59 oral anticoagulation 59 adjuvant therapies 59 comorbid anxiety 59 affective disorders 59 interventions 59 neurobiological mechanisms 59 biopsychosocial model 59 hypomanic episodes 59 lipid lowering medication 59 stratifying patients 59 pathologic fractures 59 chronicity 59 comorbid psychiatric 59 anticholinergic drugs 59 bone metabolism 59 psychiatric comorbidity 59 subclinical atherosclerosis 59 thrombotic complications 59 VADT 59 p# activation 59 immunosuppressive regimens 59 Vitamin D supplementation 59 pathophysiological processes 59 T1DM 59 antiplatelet medications 59 dietary modification 59 intranasal corticosteroids 59 subclinical disease 59 pharmacodynamic parameters 59 treating neuropathic pain 59 myocardial dysfunction 59 etiologic factors 59 APOE genotype 59 affective psychoses 59 OSAHS 59 MBCT 59 Cognitive behavioral therapy 59 randomized controlled trials 59 antihypertensive therapy 59 oral NSAIDs 59 underdiagnosis 59 thiopurine 59 metabolic parameters 59 anticholinergic agents 59 neurobiological underpinnings 59 anticholinergic effects 59 androgen suppression 59 unmeasured confounders 59 micronutrient intake 59 Psychosocial interventions 59 cardioprotection 59 renoprotective 59 silent myocardial ischemia 59 androgen depletion therapy 59 comorbid conditions 59 radiographic findings 59 antidepressant monotherapy 59 CaPre ™ 59 randomized controlled trials RCTs 59 cranial irradiation 59 neurologic disorders 59 intracerebral haemorrhage 59 metaanalysis 59 neurodevelopmental outcomes 59 neurodevelopmental outcome 59 glial tumors 59 abstinent alcoholics 59 proliferative diabetic retinopathy 59 anticonvulsant medications 58 CLA supplementation 58 thrombolytic agents 58 glitazones 58 diabetic polyneuropathy 58 pathogenetic mechanisms 58 shorter telomere length 58 neuroinflammation 58 psychiatric comorbidities 58 mixed hyperlipidemia 58 potentially modifiable 58 immunomodulation 58 lipid lowering therapies 58 adenoidectomy 58 remyelination 58 neurocognitive impairment 58 euthymic patients 58 TNF antagonist 58 melatonin supplements 58 pathophysiologic 58 synaptic function 58 vasodilatation 58 Pathological gambling 58 adult neurogenesis 58 symptomatology 58 hypoglycemic episodes 58 daytime drowsiness 58 neuroleptic drugs 58 mTOR inhibition 58 topical calcineurin inhibitors 58 trastuzumab Herceptin ® 58 inhaled glucocorticoids 58 nonadherence 58 atypical antipsychotic medications 58 molecular mechanisms underlying 58 cortical excitability 58 paricalcitol 58 Pharmacologic 58 cognitive enhancer 58 oral corticosteroid 58 empirically validated 58 Zevalin consolidation 58 endocrine therapies 58 CYP#D# inhibitors 58 thoracoscopic lobectomy 58 neuroanatomical 58 aldosterone antagonists 58 cyclic HMB 58 aromatase inhibitors AIs 58 perfusion CT 58 neurobiological basis 58 vitamin D supplementation 58 lipid lowering therapy 58 tumor subtype 58 methodological limitations 58 lethal arrhythmias 58 biologic pathways 58 paroxetine Paxil 58 antipsychotic induced 58 postoperative atrial fibrillation 58 circadian misalignment 58 neurocognitive functioning 58 psychodynamic therapy 58 statin medications 58 interferon therapy 58 clefting 58 allogeneic HSCT 58 androgen therapy 58 resynchronization therapy 58 perfusion abnormalities 58 riociguat 58 antiplatelet drugs 58 acamprosate 58 Bisphosphonate 58 uric acid lowering 58 meta regression 57 creatine supplementation 57 convergent validity 57 serotonin deficiency 57 anti angiogenic drugs 57 immunological responses 57 guideline concordant 57 depression suicidal ideation 57 DHEA supplementation 57 overactive bladder symptoms 57 immunosuppressive therapies 57 adjuvant systemic 57 anticoagulant warfarin 57 oxcarbazepine 57 neuroprotection 57 nerve degeneration 57 serotonin reuptake inhibitors 57 growth hormone secretion 57 neurosensory 57 RCTs 57 RISPERDAL ® 57 nonsurgical treatments 57 thromboembolic disease 57 subclinical cardiovascular disease 57 perinatal outcomes 57 cardio protective 57 antidepressants SSRIs 57 antenatal depression 57 coadministration 57 LLLT 57 intravenous cyclophosphamide 57 newer atypical antipsychotics 57 potassium sparing diuretics 57 coronary revascularization procedures 57 Genetic variants 57 MS relapses 57 psychosocial functioning 57 symptomatic hyponatremia 57 periprocedural MI 57 neural degeneration 57 nongenetic 57 pathogenic mechanisms 57 postoperative mortality 57 pharmacotherapy 57 neuronal function 57 syndromal 57 hippocampal neurogenesis 57 methotrexate therapy 57 lipid lowering medications 57 causal pathways 57 androgen excess 57 mTOR inhibitors 57 decompensated cirrhosis 57 leukotriene receptor antagonists 57 beta blocker therapy 57 antitumour 57 cognitive domains 57 therapy CBT 57 molecular abnormalities 57 prefrontal regions 57 dietary carbohydrate 57 Muscle relaxants 57 activate AMPK 57 chronic LBP 57 DMARDS 57 tranylcypromine 57 lumbar disk herniation 57 hawthorn extract 57 Interpersonal psychotherapy 57 neuroinflammatory 57 physiological adaptations 57 pleiotropic effects 57 akinetic mutism 57 direct thrombin inhibitors 57 #beta HSD1 57 dyslipidaemia 57 STEP BD 57 opioid analgesia 57 neuropsychological functioning 57 meta analytic review 57 microvascular complications 57 cataract formation 57 QTc intervals 57 lipid parameters 57 airway responsiveness 57 lipid abnormalities 57 reflux symptoms 57 inhaled corticosteroid therapy 57 immune reconstitution 57 methodologic 57 psychostimulants 57 sotalol 57 orofacial pain 57 hypoxemia 57 familial clustering 57 aetiology 57 sedating medications 57 psychosocial 57 psychobiological 57 atherogenic dyslipidemia 57 aminotransferases 57 diabetic kidney 57 cholinesterase inhibitors 57 cardiovascular morbidity 57 thyroid dysfunction 57 meta analyzes 57 adiponectin levels 57 dysfunctional voiding 57 warfarin therapy 57 subsyndromal 57 physiological mechanisms 57 physiologic responses 57 immunosuppressive agents 57 Aggrastat ® tirofiban hydrochloride 57 Caloric restriction 57 proliferative retinopathy 57 EEG abnormalities 57 psychosocial interventions 57 inotropic 57 hippocampal function 57 stochastic resonance 57 obstetric complications 57 urate levels 57 Glucocorticoids 57 aldosterone antagonist 57 ischemic cardiomyopathy 57 infantile colic 57 telomere lengths 57 neuronal plasticity 57 apneic episodes 57 lenalidomide dexamethasone 57 differential gene expression 57 acting insulin analogues 57 uncontrolled epilepsy 57 SSRI antidepressant 57 Wernicke Korsakoff syndrome 57 pain syndromes 57 intravenous bisphosphonates 56 hormone therapy HT 56 motor neuron degeneration 56 NNT = 56 HER2 overexpression 56 recurrent venous thromboembolism 56 neurogenerative diseases 56 serum lipid 56 atherosclerosis regression 56 HIV lipodystrophy 56 cardiotoxic effects 56 receptor subtypes 56 intensive statin therapy 56 pathophysiology 56 vidofludimus 56 coinfected patients 56 myocardial reperfusion 56 oncologic outcomes 56 TMJD 56 adjunctive therapies 56 monoamine oxidase inhibitors 56 Combination therapy 56 ovarian hormones 56 Helicobacter pylori eradication 56 mGluR2 NAM 56 Adjuvant chemotherapy 56 macrovascular disease 56 ziconotide 56 somatostatin analogs 56 neurotrophic 56 noncardiac chest pain 56 myopathy rhabdomyolysis 56 physiologic 56 COPD exacerbations 56 LHRH antagonists 56 intravenous immunoglobulin IVIg 56 canakinumab 56 antiepileptics 56 vitamin supplementation 56 N acetylcysteine 56 Comorbid 56 arterial calcification 56 imipramine 56 rBChE 56 virological response 56 tic disorders 56 electroconvulsive therapy ECT 56 NMDA antagonists 56 thyrotropin levels 56 periodontal diseases 56 hematopoietic cancers 56 extrapyramidal symptoms 56 antiarrhythmic drugs 56 CYP#D# inhibitor 56 carotid IMT 56 erlotinib Tarceva 56 antimicrobial prophylaxis 56 neurological abnormalities 56 chromium supplementation 56 mitochondrial toxicity 56 variant angina 56 eculizumab therapy 56 etiologic 56 Valdoxan 56 familial predisposition 56 unmeasured confounding 56 Subgroup analyzes 56 Mood disorders 56 antiarrhythmic drug 56 ski lls 56 TNF alpha inhibitor 56 randomized trials 56 syncopal episode 56 prodromal symptoms 56 imexon 56 mechanistic explanation 56 colorectal adenoma 56 autonomic dysfunction 56 glucocorticoid hormones 56 COMT inhibitors 56 steroid inhalers 56 IBS sufferers 56 psychotic illnesses 56 Cognitive Behavioural Therapy CBT 56 L dopa 56 mPFC 56 schizotypal traits 56 prospective observational studies 56 neuromotor 56 adrenal suppression 56 FSAD 56 clomipramine 56 biological plausibility 56 lowering homocysteine 56 Hypoglycaemia 56 venous thromboembolic disease 56 thromboprophylaxis 56 folinic acid 56 Mindfulness Based Cognitive Therapy 56 LTRA 56 ConclusionThis 56 comorbid illnesses 56 neuroinflammatory diseases 56 C1 INH deficiency 56 Longitudinal studies 56 bronchopulmonary dysplasia BPD 56 clinically meaningful reductions 56 nonepileptic seizures 56 authors conclude 56 beta1 integrin 56 metabolic dysfunction 56 CYP #A# 56 antiarrhythmic medications 56 nonalcoholic steatohepatitis 56 neural substrates 56 mechanistic insights 56 premenstrual symptoms 56 intracranial stenosis 56 mechanistic studies 56 CART peptides 56 cholinergic tone 56 tic severity 56 adenotonsillectomy 56 pharmacokinetic interactions 56 bowel resection 56 morbidities 56 thiazide 56 asthma exacerbations 56 antiandrogens 56 cerebral ischemia 56 cranial radiation 56 amyloid deposition 56 Insulin detemir 56 recurrent miscarriage 56 dyslipidemias 56 glucose homeostasis 56 inhibitory neurotransmitters 56 risperidone Risperdal 56 nonoperative treatment 56 endophenotypes 56 LDL lowering 56 symptomology 56 hypoperfusion 56 Cortisone injections 56 psychotherapeutic treatments 56 epigenetic mechanisms 56 behavioral disinhibition 56 chemopreventive agents 56 acute mania 56 adenoma recurrence 56 cardiometabolic disorders 56 methodologically rigorous 56 allostatic load 56 oncomodulin 56 electrophysiologic 56 therapeutic armamentarium 56 euthymic 56 improves insulin sensitivity 56 parkinsonian 56 Heavy snorers 56 hypertension diabetes mellitus 56 DNA demethylation 56 neuro psychiatric disorders 56 amyloid plaque formation 56 neurosteroid 56 neurochemistry 56 intracranial hemorrhage ICH 56 postmenopausal hormone therapy 56 anti TNFs 56 Alequel 56 beta agonists 56 inotropic agents 56 symptom flare ups 56 recurrent DVT 56 EXJADE 56 CPAP adherence 56 venlafaxine Effexor 56 arterial thickening 56 baroreflex 56 hemoglobin A1c levels 56 loop diuretics 56 glucocorticoid therapy 56 GBA mutations 56 curative resection 56 motivational interviewing 56 periodontal infections 56 sensory gating 56 neuropsychiatric disorders 56 cardiac repolarization 56 CORE OM 56 paclitaxel eluting stents 56 perioperative complications 56 serum calcium levels 56 hippocampal atrophy 56 longitudinal studies 56 parasomnias 56 macrovascular events 56 Meta analyzes 56 oral antidiabetes drugs 56 BoNTA 56 meta cognitive 56 systemic corticosteroid 56 Oral corticosteroids 55 COX enzymes 55 androgen deficiency 55 CB1 antagonists 55 antihypertensive agents 55 antiepileptic medications 55 hyperuricaemia 55 H. pylori eradication 55 prognostic markers 55 developmental trajectories 55 elevated CRP 55 atherogenesis 55 plasma homocysteine 55 angiographic outcomes 55 hereditary predisposition 55 neuroprotective therapies 55 antithrombotic therapies 55 internalizing disorders 55 noxious stimuli 55 depressive symptom 55 CLBP 55 flecainide 55 EFFEXOR XR 55 airway narrowing 55 elevated homocysteine 55 biphosphonates 55 menopausal symptom 55 psychiatric morbidity 55 migraineurs 55 vascular dysfunction 55 conventional angiography 55 postoperative complication 55 COX inhibitors 55 serum PTH 55 insulin analogs 55 thiazide diuretic 55 INVEGA ® 55 delayed gastric emptying 55 comorbid psychiatric disorders 55 deferiprone 55 analgesic effects 55 neutropenic patients 55 severe hypoglycaemia 55 chronic periodontitis 55 MMSE scores 55 CYT# potent vascular disrupting 55 psychotherapeutic 55 behavioral disturbances 55 symptomatic VTE 55 causal pathway 55 PDE 5i 55 comorbid diagnoses 55 coagulopathy 55 neurobiological 55 inflammatory bowel syndrome 55 subthreshold depression 55 hemodilution 55 developmental neurotoxicity 55 carbohydrate restriction 55 SILENOR 55 Posttraumatic stress disorder PTSD 55 antiplatelet agents 55 hypothalamic pituitary adrenal axis 55 protein misfolding diseases 55 cartilage degeneration 55 morphometric vertebral fractures 55 preoperative chemotherapy 55 artery stenosis 55 vasodilators 55 cortical stimulation 55 maintaining cardiorespiratory fitness 55 oral anticoagulant therapy 55 androgen hormone 55 incidentalomas 55 anticonvulsants 55 postoperative morbidity 55 VEGF inhibitors 55 impulsive behaviors 55 cognitive behavioral therapy 55 IOP lowering 55 antidepressant medications 55 plasma glucose concentration 55 amisulpride 55 EDEMA3 trial 55 tricyclic antidepressants 55 pre operatively 55 IV bisphosphonates 55 Clot busting 55 dietary folate 55 neuropsychological evaluations 55 atypical femur fractures 55 haematologic 55 ovarian suppression 55 CIMZIA ™ 55 disordered eating patterns 55 Thal Dex 55 comorbidities 55 anti androgens 55 BEXXAR therapeutic regimen 55 abrupt discontinuation 55 predisposing factor 55 iron chelators 55 androgenic hormones 55 cardiac abnormalities 55 OAB symptoms 55 antiangiogenic drugs 55 dietary supplementation 55 neuro protective 55 folate supplementation 55 prognostic variables 55 HIF PH inhibitors 55 Calcium intake 55 premorbid 55 CRT ICD 55 cardiotoxic 55 tissue fibrosis 55 endocrinologic 55 anticancer treatments 55 fermentable carbohydrates 55 antiemetics 55 Dose adjustments 55 insulin sensitizing 55 serum biomarkers 55 ocular disorders 55 rheumatic disorders 55 clinically meaningful 55 antiandrogen 55 Korsakoff syndrome 55 Th2 responses 55 heritable disorders 55 spontaneous regression 55 COPD sufferers 55 antiinflammatory drugs 55 microvascular disease 55 hypotensive 55 Randomised controlled trials 55 neurological impairments 55 endogenous opioid 55 rEV# 55 β blocker 55 Richard Suzman Ph.D. 55 phosphodiesterase inhibitors 55 lowering blood glucose 55 vascular abnormalities 55 rheumatic diseases 55 lupus scleroderma 55 pramlintide metreleptin combination 55 surrogate markers 55 fibrotic disease 55 fulvestrant 55 etiological 55 Prostatitis 55 HIV HCV coinfected 55 antidiabetic medications 55 fatal arrhythmias 55 Heritability 55 rufinamide 55 galanin 55 HAART regimens 55 pouchitis 55 stimulant ADHD 55 somatoform disorder 55 imatinib therapy 55 nondepressed 55 neuropathy nerve 55 oral prednisolone 55 hormone deprivation 55 NATRECOR R 55 neurodevelopmental disorders 55 anorexia nervosa bulimia nervosa 55 autoantibody levels 55 hedgehog signaling 55 placebo controlled studies 55 metastatic bone 55 intravesical therapy 55 extramedullary 55 serum estradiol 55 Adequate vitamin D 55 severe hypoglycemia 55 Kaplan Meier curve 55 HeFH 55 prazosin 55 epidural steroid injections 55 atherothrombotic 55 Parkinsonian symptoms 55 sideeffects 55 sulphonylureas 55 thyrotropin 55 macrovascular complications 55 rheumatological 55 levodopa carbidopa 55 neuroactive 55 multivitamin supplementation 55 fragility fracture 55 erythropoietic 55 immunomodulatory agents 55 primidone 55 Adverse effects 55 pregnancy lactation 55 insulin sensitization 55 hippocampal volume 55 primary aldosteronism 55 topical retinoids 55 TNF inhibitors 55 plasma lipid 55 immune modulating 55 antianginal 55 posttraumatic 55 PTEN protein 55 EEG biofeedback 55 behavioral abnormalities 55 epigenetic changes 55 opioid dependent 55 SERMs 55 ketogenic diet 55 posttransplant 55 prenatal exposures 55 maturational 55 idraparinux 55 glycemic diet 55 ventricular remodeling 55 systemic hypotension 55 thrombophilia 55 Elevated triglycerides 55 Severe Primary IGFD 55 QT interval prolongation 55 endocrinological 55 Randomized trials 55 sertraline Zoloft 55 Imipramine 55 PASI scores 55 pulmonary toxicity 55 atrial tachyarrhythmias 55 JAK STAT pathway 55 A1c levels 55 cognitive functioning 55 Pagoclone 55 PPAR gamma agonists 55 neuroregenerative 55 metabolic disturbances 55 caspofungin 55 atherosclerotic renal artery stenosis 55 asymptomatic carotid stenosis 55 late onset hypogonadism 55 generalisability 55 oncological outcomes 55 prostanoid 55 CTAP# Capsules 54 vascular endothelial dysfunction 54 fluoxetine paroxetine 54 induce orthostatic hypotension 54 platelet inhibition 54 colorectal adenomas 54 anticlotting drugs 54 G6PD deficiency 54 comorbidity 54 Calcium vitamin D 54 chemopreventive agent 54 diabetic gastroparesis 54 radiographic outcomes 54 torsade de pointes 54 Molly Wagster 54 reperfusion injury 54 plasma lipids 54 neuropathologic 54 tamoxifen metabolism 54 predictive biomarkers 54 anti dyslipidemic 54 Chronic pancreatitis 54 antitumor efficacy 54 psychophysiological 54 dosage regimens 54 intracranial atherosclerosis 54 antidiabetic drugs 54 hormonal deficiencies 54 PPARγ 54 glucocorticoids 54 cognitive affective 54 hyperglycaemia 54 Major Depressive Disorder 54 depressive symptomatology 54 cognitive behavioral 54 dissociative symptoms 54 nonsteroidal antiinflammatory drugs 54 antidiabetic therapy 54 Observational studies 54 antiarrhythmic 54 nocturnal hypoglycaemia 54 geriatric syndromes 54 residual confounding 54 nosology 54 muscular dystrophies 54 cortisol secretion 54 immunostimulatory effects 54 Homeopathic medicines 54 nonfasting triglyceride levels 54 prodromal phase 54 affective psychosis 54 anticancer therapy 54 Schema Therapy 54 mood disorders 54 HRQL 54 adrenal hormones 54 COREG 54 acute GVHD 54 mGluR5 inhibitors 54 malabsorptive 54 cerebral vasospasm 54 HIF PHIs 54 confounding variables 54 cardiomyocyte proliferation 54 extrapyramidal symptoms EPS 54 etiological factors 54 memantine Namenda 54 myoclonus 54 neurohormones 54 chromium picolinate supplementation 54 reinfarction 54 nicardipine 54 untreated OSA 54 neovascular diseases 54 transdermal estrogen 54 maximally tolerated lipid lowering 54 anxiolytics 54 inhaled budesonide 54 hydrolyzed formula 54 clevidipine 54 Transcranial Magnetic Stimulation TMS 54 biomarker identification 54 anti angiogenic agents 54 corticosteroid injections 54 urinary symptoms 54 tumor histology 54 stimulant medications 54 insomnia sufferers 54 T2DM 54 vitamin B1 deficiency 54 NSAID induced 54 neurological degeneration 54 urothelial cancer 54 linear pharmacokinetics 54 palliation 54 locomotor training 54 PPAR γ 54 microvascular dysfunction 54 constipation OIC 54 lung cancer chemoprevention 54 thiazides 54 G. biloba 54 CYP#A# inhibitors 54 levodopa therapy 54 lipid lowering drugs 54 opiate analgesics 54 lipid profiles 54 levodopa induced 54 type2 diabetes 54 maladaptive 54 PNH patients 54 gemifloxacin 54 neuropathies 54 efficacious therapies 54 serotonergic 54 Th2 cytokines 54 unresectable tumors 54 neurologic progression 54 prescribed opioids 54 neurophysiologic 54 PECAM 1 54 neuroprotective agent 54 ginkgo biloba extract 54 nonalcoholic steatohepatitis NASH 54 neurologic outcomes 54 MMP inhibitors 54 tumor hypoxia 54 surgical revascularization 54 TNF inhibitor 54 skeletal metastases 54 chemopreventive 54 univariate analyzes 54 pediatric bipolar disorder 54 IKK2 54 contrast induced nephropathy 54 secretin 54 APTIVUS r 54 myocardial ischemia 54 inflammatory polyarthritis 54 Inhaled nitric oxide 54 HbF